1. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease
- Author
-
M W Carroll, R Hewson, A Miloszewska, Geoff Pearson, S J D Findlay-Wilson, Emma Rayner, K R Buttigieg, Stuart D. Dowall, and Victoria A. Graham
- Subjects
0301 basic medicine ,Crimean–Congo hemorrhagic fever ,viruses ,Immunology ,Chick Embryo ,Receptor, Interferon alpha-beta ,Antibodies, Viral ,Virus ,Cell Line ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,Viral Proteins ,Immune system ,Immunogenicity, Vaccine ,Crimean-Congo hemorrhagic fever, nucleoprotein, protection, vaccine ,Cricetinae ,Chlorocebus aethiops ,Immunology and Allergy ,Medicine ,Animals ,Humans ,Vector (molecular biology) ,Vero Cells ,Pharmacology ,Mice, Knockout ,Vaccines, Synthetic ,business.industry ,Immunogenicity ,Viral Vaccine ,Viral Vaccines ,Viral Load ,medicine.disease ,Virology ,Research Papers ,Nucleoprotein ,030104 developmental biology ,Nucleoproteins ,chemistry ,Hemorrhagic Fever Virus, Crimean-Congo ,Hemorrhagic Fever, Crimean ,Immunization ,Vaccinia ,business - Abstract
Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15-70% of reported cases are fatal with no approved vaccine available. In the present study, the attenuated poxvirus vector, Modified Vaccinia virus Ankara, was used to develop a recombinant candidate vaccine expressing the CCHF virus nucleoprotein. Cellular and humoral immunogenicity was confirmed in 2 mouse strains, including type I interferon receptor knockout mice, which are susceptible to CCHF disease. Despite the immune responses generated post-immunisation, the vaccine failed to protect animals from lethal disease in a challenge model.
- Published
- 2015